Therapy of a murine lymphoma with tumor-specific antiserum in combination with adriamycin, cyclophosphamide, or L-asparaginase.
Therapy of the 6C3HED lymphoma in syngeneic C3H/HeN mice was studied using tumor-specific antiserum in combination with adriamycin, cyclophosphamide, or L-asparaginase. Antiserum therapy is only effective in the control of small numbers of tumor cells, and cell cures were only obtained when this number did not exceed 5 x 10(5). Complete suppression of larger numbers of tumor cells (10(6) to 5 x 10(7)) could be achieved with the inclusion of chemotherapy at levels that reduced the tumor cell number to less than 10(5) in the case of L-asparaginase and less than 10(4) with cyclophosphamide and adriamycin. The differences in drug cooperative effectiveness are likely to be due to drug-induced impairment of macrophage mobilization to the tumor site.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D007116:Immunization, Passive; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009135:Muscular Diseases / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy
D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase